树脂菌 (dendrobium officinale) 的低血糖效应会使叶子出现低血糖
Ming Lv1,2, Qingqing Liang1,3, Xiaofang He4
1College of Food Science and Technology, Yunnan Agricultural University, Kunming, China.
Frontiers in pharmacology
|June 26, 2023
概括
该研究发现,Dendrobium officinale叶子提取物 (EDL) 能够有效降低血糖,并改善高脂肪饮食小鼠的葡萄糖耐受性. 低血糖效应与激活胰岛素信号通路有关,其中关键活性化合物在提取物>3kDa部分中发现.
科学领域:
- 药理学和传统医学的医学.
- 代谢性疾病研究研究
- 植物衍生疗法 植物衍生疗法
背景情况:
- Dendrobium officinale的茎因其降糖作用而闻名,但其叶子的潜力仍然在很大程度上未被探索.
- 了解D. officinale叶的低血糖机制可以为代谢障碍提供新的治疗策略.
研究的目的:
- 调查Dendrobium officinale叶子提取物 (EDL) 的低血糖作用和潜在机制.
- 为了确定EDL中负责葡萄糖调节的活性成分.
主要方法:
- 在体内研究:高脂肪或标准饮食的C57BL/6小鼠接受了EDL16周,监测代谢参数.
- 实验室研究:C2C12神经细胞和HEPA细胞被EDL治疗,以评估胰岛素信号通路激活和肝脏葡萄糖代谢.
- 组件分析:EDL通过乙醇提取和超过来分化,以分离和测试活性化合物 (> 3 kDa 和 <3 kDa 分数).
主要成果:
- 在高脂肪饮食养的小鼠中,EDL显著降低了血糖水平,改善了葡萄糖耐受性,但在标准饮食养的小鼠中没有影响.
- 在体外,EDL通过增加Akt酸化和C2C12细胞下游GSK3β表达来激活胰岛素信号通路.
- EDL没有影响HEPA细胞中的肝脏葡萄糖生成或糖原合成;超过3kDa的乙醇溶解分量 (ESFE) 显示出显著的低血糖活性.
结论:
- 丹德罗 (Dendrobium officinale) 树叶提取物 (EDL) 主要通过激活胰岛素信号通路来增强胰岛素敏感性来产生低血糖作用.
- 负责降糖效果的主要活性化合物存在于EDL的3kDa以上的乙醇溶解分量中.
- 这些发现为开发D. officinale叶作为管理高血糖和改善胰岛素敏感性的潜在治疗剂提供了科学基础.
相关概念视频
Hypoglycemia and Glucagon
306
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306
Oral Hypoglycemic Agents: Glinides
189
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
189
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
210
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
210
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
Hormones Regulating Blood Glucose
3.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240


